AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21614939
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine approach (six group sessions on nutritional manipulation, yoga techniques, journaling, plus nutritional supplements: fish oil, vitamin C, standardized hops extract)
Trial: 21614939
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine approach
Trial: 19548250
Drug: CAMHS outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMHS outpatient treatment
Trial: 20334748
Drug: Specialist outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist outpatient treatment
Trial: 9485979
Drug: Pre-operative administration
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative administration of bupivacaine
Trial: 9485979
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of bupivacaine
Trial: 8379174
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) retrograde injection
Trial: 30839100
Drug: Cycle-Specific Risk
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle-Specific Risk of Febrile Neutropenia after Chemotherapy score (CSRFENCE score)
Trial: 26879276
Drug: Ozanimod 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 1 mg
Trial: 24474034
Drug: E2/LNG Low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/LNG Low TDS (4.4 mg E2 and 1.39 mg LNG)
Trial: 24474034
Drug: E2/LNG High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/LNG High TDS (4.4 mg E2 and 2.75 mg LNG)
Trial: 24474034
Drug: E2 0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 0.050 mg/24 hours TDS and 0.090 mg LNG oral tablet
Trial: 15638905
Drug: Doxazosin extended-release
RxNorm normalized name: doxazosin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin extended-release (XL) 4 or 8 mg once daily for 13 weeks
Trial: 15638905
Drug: Doxazosin standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin standard 1-8 mg once daily for 13 weeks
Trial: 11942178
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (chemotherapy, radiotherapy, multimodal treatments)
Trial: 10091516
Drug: Home intravenous
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home intravenous antibiotic therapy
Trial: 10091516
Drug: Hospital intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital intravenous antibiotic therapy
Trial: 31924257
Drug: Regular gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular gel or silicone liners for 6 months
Trial: 31112620
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice/day
Trial: 31112620
Drug: Lower than
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower than recommended dosing of apixaban
Trial: 31112620
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg twice/day
Trial: 31112620
Drug: Recommended dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dosing of 5 mg twice/day
Trial: 27430990
Drug: Bupivacaine lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine lozenge (25 mg) administered as single dose to HNC patients with oral mucositis
Trial: 27430990
Drug: Bupivacaine lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine lozenge (25 mg) administered as multiple doses to HNC patients with oral mucositis
Trial: 27430990
Drug: Bupivacaine lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine lozenge (5, 10, 25, and 50 mg) administered as single dose to healthy individuals
Trial: 18563473
Drug: Parent training
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent training combined with child therapy (PT + CT)
Trial: 7523775
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg estradiol valerate
Trial: 6363985
Drug: tiropramide hydrochloride
RxNorm normalized name: tiropramide hydrochloride
DrugBank: Tiropramide (DB13091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiropramide hydrochloride (300 mg daily for 30 days)
Trial: 6363985
Drug: octylonium bromide
RxNorm normalized name: octylonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octylonium bromide (120 mg daily)
Trial: 27049275
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of magnesium sulfate
Trial: 22350328
Drug: Mentha crispa
RxNorm normalized name: Mentha crispa oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentha crispa (24 mg)
Trial: 22350328
Drug: Secnidazole (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole (2,000 mg)
Trial: 17381122
Drug: Dried cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cranberry juice (DCJ) 1200 mg/day
Trial: 17381122
Drug: Dried cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cranberry juice (DCJ) 400 mg/day
Trial: 11049910
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluvoxamine and erythromycin
Trial: 28748081
Drug: 225 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 μg iodine as potassium iodide capsule daily for 6 months
Trial: 28748081
Drug: 450 g
RxNorm normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 g of appropriately iodized salt (30‐40 μg I as KIO3/g of salt) weekly for household consumption for 6 months
Trial: 19218540
Drug: Intensified extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified extended dialysis (IED) therapy, dosed to maintain plasma urea levels <90 mg/dL (<15 mmol/L)
Trial: 19218540
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis (SED) therapy, dosed to maintain plasma urea levels between 120 and 150 mg/dL (20‐25 mmol/L)
Trial: 11376910
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 0.5 mg/kg bolus followed by 0.25 mg/kg per h (group 3)
Trial: 11376910
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 0.25 mg/kg bolus followed by 0.125 mg/kg per h (group 2)
Trial: 11376910
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine 0.25 mg/kg and 0.125 mg/kg per h (group 4)
Trial: 11376910
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine 0.5 mg/kg and 0.25 mg/kg per h (group 5)
Trial: 7683942
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (intravenous leucovorin 200 mg/m2/day, 5-fluorouracil 550 mg/m2/day, cisplatin 20 mg/m2/day for four week cycles)
Trial: 3828169
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl anaesthesia (100 micrograms/kg body weight)
Trial: 26602782
Drug: Daily sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sedation interruption plus protocolized sedation (DSI + PS)
Trial: 25544955
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of ketamine plus 2 mL of bupivacaine 0.5%
Trial: 25544955
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of normal saline plus 2 mL of bupivacaine 0.5%
Trial: 25544955
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of normal saline
Trial: 22240782
Drug: P-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-containing therapy
Trial: 15933509
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral antibiotics
Trial: 12075761
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (100,000 IU/kg/day in three divided doses for 10 days)
Trial: 7636641
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate)
Trial: 7636641
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate) in black subjects
Trial: 7636641
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (600 mg calcium as calcium citrate malate) based on baseline calcium intake quartiles
Trial: 2651327
Drug: Oral vasodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vasodilators
Trial: 336116
Drug: Schedule I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule I: Prednisone plus chlorambucil (CLB) given as a once-a-month dose of 0.4-0.8 mg/kg
Trial: 336116
Drug: Schedule II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule II: Prednisone plus chlorambucil (CLB) given as a daily dose of 0.08 mg/kg
Trial: 23860024
Drug: Naturopathic reflex
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic reflex therapies (massage, Gua Sha massage, cupping, wet packs, rhythmic embrocation)
Trial: 23860024
Drug: Naturopathic reflex
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic reflex therapies
Trial: 15526716
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) treatment
Trial: 9599737
Drug: After treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After treatment
Trial: 11091828
Drug: Topical ethanol
RxNorm normalized name: ethanol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ethanol applied to the operative site for three minutes
Trial: 11091828
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received the same analgesic protocol including infiltration of the operative site with ropivacaine
Trial: 9372359
Drug: Allylamine preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allylamine preparations and ciclopirox olamine
Trial: 1403038
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 25 mg/m2/d times three, intravenous (IV) bolus plus cisplatin (CDDP) 100 mg/m2, 24 hour infusion, every 3 weeks times six; preceded by high-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four.
Trial: 1403038
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) 8 g/m2, 6-hour infusion, every 4.5 weeks times four, followed by Doxorubicin (DOX) and Cisplatin (CDDP).
Trial: 31593709
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg i.v. citalopram
Trial: 31593709
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg citalopram
Trial: 25751386
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution group (treatment group)
Trial: 23245621
Drug: Optimal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal standard therapy
Trial: 21676008
Drug: Pharmacobehavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacobehavioral treatment
Trial: 17672828
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) using recombinant human ASB (rhASB)
Trial: 14959954
Drug: Bisphosphonate infusion
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate infusion (pamidronate or clodronate)
Trial: 8678396
Drug: Warfarin vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin vs Aspirin in patients older than 75 years
Trial: 6693580
Drug: lorazepam infusion
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lorazepam infusion at two different rates
Trial: 15037537
Drug: Chlorthalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (50 mg/d)
Trial: 2877644
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy with chlorthalidone
Trial: 28152655
Drug: del Nido
RxNorm normalized name: Del Nido Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: del Nido (DN) solution
Trial: 28152655
Drug: modified St.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified St. Thomas' (MST) cardioplegia solution
Trial: 11029345
Drug: pH-corrected group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-corrected group (THAM administered)
Trial: 11029345
Drug: pH-uncorrected group
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-uncorrected group (no THAM administered)
Trial: 8816034
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional iron treatment)
Trial: 1486738
Drug: 1 alpha-hydroxy
RxNorm normalized name: alpha hydroxy acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha-hydroxy vitamin D3 (1 microgram/day) and 500 mg of calcium
Trial: 30865304
Drug: Preventure program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventure program (cognitive behavioral therapy-based group sessions targeting personality risk profiles)
Trial: 23415907
Drug: Total glucosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total glucosides of paeony (TGP) in combination with methotrexate (MTX 10 mg/week) and leflunomide (LEF 20 mg/day)
Trial: 23415907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (MTX 10 mg/week plus LEF 20 mg/day without TGP)
Trial: 17061632
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 2 mg/kg with clonidine 2 microg/kg (group BUP+CLO)
Trial: 17061632
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 2 mg/kg (group BUP)
Trial: 773180
Drug: Single antibiotic
RxNorm normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single antibiotic therapy
Trial: 26272173
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin detemir
Trial: 23317685
Drug: Buprenorphine-naloxone tablets
RxNorm normalized name: buprenorphine / naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone tablets
Trial: 16951997
Drug: Tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1 mg/kg intravenously over 2.5 min)
Trial: 16951997
Drug: Tramadol (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (additional 0.33 mg/kg if pain relief was inadequate)
Trial: 20558416
Drug: Indometacin (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (100-200 mg intramuscularly or orally)
Trial: 20558416
Drug: Indometacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (oral or intramuscular)
Trial: 18216286
Drug: l‐NMMA (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐NMMA (0.2 mg . min(‐1) dl(‐1) forearm)
Trial: 18216286
Drug: Aprepitant (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (375 mg orally)
Trial: 12192262
Drug: Anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory drugs
Trial: 28914131
Drug: AbobotulinumtoxinA injections
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA injections (maximum total dose per injection cycle: 30 U/kg or 1000U) into the gastrocnemius-soleus complex and other muscles as required.
Trial: 26030111
Drug: Inhalation challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation challenges with terpenes and terpenoids
Trial: 26030111
Drug: Intradermal challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal challenges with volatile organic compounds (VOCs) including terpenes and terpenoids
Trial: 26030111
Drug: Inhaled challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled challenges
Trial: 26030111
Drug: Intradermal challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal challenges
Trial: 21388456
Drug: Oral retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral retinoids (dosages between 10 and 25 mg, with stepwise escalation)
Trial: 21388456
Drug: Retinoids as
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinoids as single agent therapy
Trial: 14644692
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of CONSORT guidelines in behavioral medicine research
Trial: 14644692
Drug: Behavioral medicine-specific
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral medicine-specific guidelines (e.g., treatment adherence)
Trial: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 50 mg/m² IV on day 1 and Vinorelbine (VNB) 25 mg/m² IV on days 1 and 8 (arm 1)
Trial: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 70 mg/m² IV on day 1 (arm 2)
Trial: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 40 mg/m² IV on day 1 and Vinorelbine (VNB) 20 mg/m² IV on days 1 and 8 (arm 1) after dose reduction
Trial: 10856098
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 60 mg/m² IV on day 1 (arm 2) after dose reduction
Trial: 7474314
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg suppository just after induction of anesthesia (Group T)
Trial: 7474314
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg suppository about 90 min before incision (Group P)
Trial: 2318223
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 60 mg
Trial: 6985835
Drug: Chemoimmunotherapy (C.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (C. parvum 4 mg subcutaneously weekly, along with chemotherapy)
Trial: 6985835
Drug: Chemotherapy (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vincristine, Daunorubicin, prednisone, Cytosine Arabinoside, and 6-mercaptopurine)
Trial: 6985835
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal methotrexate (13 mg/m2)
Trial: 21270442
Drug: Lestaurtinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lestaurtinib (80 mg twice daily)
Trial: 15529604
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day + ranitidine 150 mg/day
Trial: 15529604
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day + 30 g alcohol/day
Trial: 9664981
Drug: OKT3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OKT3 treatment
Trial: 7622343
Drug: Inositol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (12 gm daily)
Trial: 29949273
Drug: Warm normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm normal saline distention solution (0.9% normal saline warmed up to 36⁰C)
Trial: 29949273
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature normal saline solution (0.9% normal saline at 25⁰C)
Trial: 25934173
Drug: PARO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARO therapy group
Trial: 9342764
Drug: LI 160
RxNorm normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI 160 (900 mg total daily dose)
Trial: 9342764
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg total daily dose)
Trial: 8213020
Drug: Cervical epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical epidural steroid/lidocaine injections (group A)